18F-FDG PET/CT在弥漫性大B细胞淋巴瘤风险分层中的应用进展OA
Research progress on the application of 18 F-FDG PET/CT in risk stratification of diffuse large B-cell lymphoma
弥漫性大B细胞淋巴瘤(DLBCL)是一种高度异质性的血液系统恶性肿瘤,预后差异显著.现行临床评分系统对于高风险患者识别能力不足,无法实现精准的风险分层.正电子发射断层显像/计算机体层成像(PET/CT)已广泛用于DLBCL患者治疗前评估,越来越多的研究表明,基于18F-FDG PET/CT的分层标志物及影像组学可预测生存结局,有助于改进DLBCL的风险分层.本综述将从PET/CT分层标志物及影像组学在DLBCL风险分层中的应用、分层策略及局限性进行综述.
Diffuse large B-cell lymphoma is a highly heterogeneous hematologic malignancy with significant differences in prognosis.Current clinical prognostic scoring systems lack the precision for accurate risk stratification,especially in identifying high-risk patients.Positron emission tomography/computed tomography has been extensively used in the pretherapeutic evaluation of diffuse large B-cell lymphoma patients.Increasing researches show that PET/CT markers and radiomic features can predict survival outcomes thereby enhancing the precision of risk stratification in DLBCL.This review focuses on the use of 18F-FDG PET/CT markers and radiomics in DLBCL risk stratification,with an emphasis on their applications,risk stratification strategy and limitations.
常国栋;赵艳萍;姚雪
新疆医科大学附属肿瘤医院核医学科,新疆 乌鲁木齐 830011新疆医科大学附属肿瘤医院核医学科,新疆 乌鲁木齐 830011新疆医科大学附属肿瘤医院核医学科,新疆 乌鲁木齐 830011
弥漫性大B细胞淋巴瘤正电子发射断层显像/计算机体层成像影像组学深度学习肿瘤代谢体积播散特征风险分层
diffuse large B-cell lymphomapositron emission tomography/computed tomographyradiomicsdeep learningmetabolic tumor volumedissemination featurerisk stratification
《分子影像学杂志》 2026 (4)
534-540,7
新疆肿瘤学重点实验室开放课题基金(XJKLO-2023U005)
评论